Metabolic interrelationships, cardiovascular disease, and sex steroids

Contraception

Volumn 57, Issue 3, 1998, Pages 183-187

  Fotherby, K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Lipid metabolism; Pharmacodynamic studies of oral contraceptives; Sex steroids

Indexed keywords

APOPROTEIN; BLOOD CLOTTING FACTOR 7; FATTY ACID; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; SEX HORMONE; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CIRCULATION; FAT INTAKE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HORMONE ACTION; HYPERINSULINEMIA; LIPID METABOLISM; METABOLIC REGULATION;

EID: 0032034148     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00017-1     Document Type: Review

References (20)

1. Katan M.B., Zock P.I., Mensink R.P. Effect of fats and fatty acids on blood lipids. Am J Clin Nutr. 60:(suppl):1994;1017S-1022S.
2. Mann J.I. Dietary effects on plasma LDL and HDL. Curr Opin Lipidol. 8:1997;35-38.
3. Mensink R.P., Katan M.B. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscl Thromb. 12:1992;911-919.
4. Goodnight S.H. Fish oil effects on atherogenesis and thrombosis . Curr Opin Lipidol. 1:1990;334-340.
5. Norday A., Hatcher L., Goodnight S., et al. Effects of dietary fat and fish oil on eicosanoid production and haemostatic parameters. J Lab Clin Med. 123:1994;914-920.
6. Storlein L.H., Baur L.A., Kriketos A.D., et al. Dietary fats and insulin action. Diabetologia. 39:1996;621-631.
7. Despres J.P. Obesity and lipid metabolism. Curr Opin Lipidol. 2:1991;5-15.
8. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
9. Taskinen M.R. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol. 6:1995;153-160.
10. Austin M.A., Edwards K.L. Small dense LDL and insulin resistance. Curr Opin Lipidol. 7:1996;167-171.
11. Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol. 7:1996;217-226.
12. Hopkins P.N., Hunt S.C., Wu L.L., et al. Hypertension, dyslipidaemia and insulin resistance. Curr Opin Lipidol. 7:1996;241-253.
13. Kostner G.M., Krempler F. Lipoprotein (a). Curr Opin Lipidol. 3:1992;279-284.
14. Zysow B.R., Lawn R.M. Relationship of lipoprotein (a) to hemostasis. Curr Opin Lipidol. 4:1993;484-489.
15. Barnathan E.S. Has lipoprotein (a) shrank? JAMA. 270:1993;2224-2225.
16. Gurewich V., Mittelman M. Lipoprotein (a) in coronary heart disease. JAMA. 271:1994;1025-1026.
17. Berg K. Lipoprotein (a) and risk of atherosclerotic/thrombotic disease. Fibrinol Proteol. 11:(suppl 1):1997;71-75.
18. Lindahl A.K. Tissue factor pathway inhibitor. Curr Opin Lipidol. 5:1994;434-439.
19. Bladbjerg EM, Marckmann P, Jespersen J. Biochemical Aspects of Dietary Factor VII Activation. PhD Thesis, South Jutland University Press, 1996.
20. Mitropoulos K.A. Lipoprotein metabolism and thrombosis. Curr Opin Lipidol. 5:1994;227-235.